Ad
related to: advances in huntington's disease treatment drugs and alcohol addiction in children- HD Chorea Resources
Find Resources for Your Patients
and Your Practice.
- Cost & Coverage Support
Learn About Cost & Coverage Support
for Your Patients with HD Chorea.
- HD Clinical Trial Results
Review Pivotal Study Results
for Huntington's Disease Chorea.
- Shared Solutions
Learn More About Teva Shared
Solutions for Your Patients.
- HD Chorea Resources
Search results
Results from the WOW.Com Content Network
The Huntington's disease Outreach Project for Education at Stanford (HOPES) is a student-run project at Stanford University dedicated to making scientific information about Huntington's disease (HD) more readily accessible to patients and the public.
Huntington's disease (HD), also known as Huntington's chorea, is an incurable neurodegenerative disease [7] that is mostly inherited. [8] The earliest symptoms are often subtle problems with mood or mental/psychiatric abilities. [9] [1] A general lack of coordination and an unsteady gait often follow. [2]
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders.It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease.
Prana Biotechnology's Huntington disease drug, PBT2, is safe, but whether it helps patients enough to get approved remains to be seen. The press release headline "Prana Announces Successful Phase ...
Under the model of alcoholism, alcohol use disorder is viewed as chronic problem for which abstinence is required. [4] A brain disease model of addiction, based on the extent of neuroadaptation and impaired control, is main position advanced for proposing a disease model of alcohol use disorder. [5]
The Journal of Huntington ' s Disease is a quarterly peer-reviewed scientific journal in neuroscience that covers all aspects of Huntington's disease and related disorders. It was established in 2012 and is published by IOS Press. The editors-in-chief are Blair Leavitt (University of British Columbia) and Leslie Thompson .
PBT2 is a safe-for-human-use Zinc ionophore [1] and an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog [ 2 ] intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease [ 3 ] and Huntington's disease .
Disease Model of addiction frames substance abuse as 'a chronic relapsing disease that changes the structure and function of the brain'. [74] Research conducted on the neurobiological factors of addiction has proven to have mixed results, and the only treatment idea it offers is abstinence. [ 75 ]
Ad
related to: advances in huntington's disease treatment drugs and alcohol addiction in children